Tag Archives: chemotherapy

Pet therapy and how it helps cancer patients

Therapy dogs may improve the emotional well-being of some cancer patients, according to results of a clinical study, the first to document the benefits of animal-assisted therapy in adult cancer patients. The research was published this month in the Journal of Community and Supportive Oncology.

The results show a significant improvement in quality of life for more than 40 patients who took part in a trial at Mount Sinai Beth Israel in New York City, where they interacted with therapy dogs following chemotherapy and radiation treatments.

Photo courtesy of The Good Dog Foundation

Photo courtesy of The Good Dog Foundation

The study, conducted by researchers at Mount Sinai Beth Israel, found that patients receiving intensive multi-modal radiation therapy and chemotherapy for gastrointestinal, head or neck cancers experienced increases in emotional well-being and quality of life when they received visits from a certified therapy dog during the course of their treatment.

Increases in emotional well-being were significant over the course of the animal-assisted visits, even as patients underwent marked and significant declines in both physical and functional well-being.

“This study is the first such definitive study in cancer, and it highlights the merits of animal- assisted visits using the same scientific standards as we hold for the cancer treatment itself. It shows the importance of an innovative environmental intervention during cancer treatment,” said Stewart B. Fleishman, MD, principal investigator and Founding Director of Cancer Supportive Services at Mount Sinai Beth Israel. “Having an animal-assisted visit significantly improved their quality of life and ‘humanized’ a high-tech treatment,” he said. “Patients said they would have stopped their treatments before completion, except for the presence of the certified Good Dog Foundation therapy dog and volunteer handler.”

“Thanks to this rigorously designed study, we now have strong evidence that pet therapy is an effective tool to help cancer patients get through challenging treatments,” said Gabriel A. Sara, MD, Medical Director, Infusion Suite at Mount Sinai Roosevelt, and Assistant Clinical Professor of Medicine, Icahn School of Medicine at Mount Sinai.

The study has been called another piece of ‘mounting evidence’ of how the human-animal bond can enhance emotional and physical health.

If you would like to pass on the journal article to your oncologist/hospital provider,  you can access it here.

Source:  EurekAlert! media release

Advertisements

Diagnosing lymphoma in dogs

Nearly one out of four dogs will develop cancer in their lifetime and 20 per cent of those will be lymphoma cases.

A team of researchers from the University of Leicester has helped Avacta Animal Health Ltd to develop a new user-friendly electronic system for diagnosing lymphoma in dogs in the early stages, and for remission monitoring.

Marketed as cLBT (canine lymphoma blood test), this is the first test of its kind to track the remission monitoring status of a dog after undergoing chemotherapy.

Photo by Avacta Animal Health Ltd

Photo by Avacta Animal Health Ltd

Led by Professor Alexander Gorban from the University’s Department of Mathematics, the University team together with experts from Avacta elaborated technology for differential diagnosis of canine lymphoma and for remission monitoring.

This technology is based on the cLBT, which detects the levels of two biomarkers, the acute phase proteins C-Reactive Protein and Haptoglobin.

The paper ‘Computational diagnosis and risk evaluation for canine Lymphoma’ by E.M. Mirkes, I. Alexandrakis, K. Slater, R. Tuli and A.N. Gorban has been published in the academic journal Computers for Biology and Medicine and is available at the following location: http://dx.doi.org/10.1016/j.compbiomed.2014.08.006

Source:  University of Leicester media release

A vaccine for canine osteosarcoma?

Osteosarcoma is a highly aggressive bone tumor that affects at least 10,000 dogs annually in the United States, alone.

Photo by osteosarcomaindogs.org

Photo by osteosarcomaindogs.org

It is estimated that 90-95 percent of canine osteosarcoma subjects have microscopic metastatic disease (spread of cancer cells to other parts of the body at the time of diagnosis). Standard of care includes removal of the primary tumor—usually by amputation—followed by chemotherapy. Systemic chemotherapy given after amputation delays the development of metastatic disease; however, despite treatment, most dogs die of the disease within one year of diagnosis.

A new option may be available in the future if Dr. Nicola Mason’s research at the University of Pennsylvania School of Veterinary Medicine produces satisfactory results. Mason, an assistant professor of medicine and a Board-certified ACVIM Diplomate in Small Animal Internal Medicine, is evaluating the first vaccine for canine osteosarcoma.

The approach harnesses the power of the dog’s immune system, “training” it to seek out and destroy cancer cells that remain after amputation and chemotherapy.

Over a century ago, an orthopedic surgeon named William Coley recognized that human sarcoma patients with concurrent bacterial infections that caused high fevers had improved overall survival times compared to those sarcoma patients without infection. This led him to develop a therapeutic concoction of live bacteria that he injected into patients with bone sarcomas. He documented improved survival and in some cases, complete remission in individuals with the aggressive disease by using this early form of “immune therapy.”

Mason’s team is employing similar immune therapeutic strategy to treat dogs with osteosarcoma that have undergone the standard of care treatment (amputation and chemotherapy) to prevent metastatic disease. “The concept is that administration of the Listeria-based (genetically modified bacteria) vaccine will activate the patient’s immune system and educate it to recognize cells that express the target molecule,” says Mason.

Dogs are given the live bacterial vaccine intravenously, Mason explains, and it induces a mild transient fever on the day of vaccination. The dogs are usually treated as outpatients and return home the same day. “We have found highly encouraging results when the vaccine is given to patients that have no evidence of metastatic disease at the time of the study enrollment, which is three weeks after the last chemotherapy is administered. Four out of the first five dogs vaccinated are alive at least two years after their initial diagnosis, which is more than twice their expected survival duration. The vaccine has not yet shown any serious short- or long-term side effects, either.”

Mason says the results have led researchers to evaluate whether this vaccine may be able to directly target and kill the bone tumor itself, perhaps eliminating the need for amputation in the future.

Source:  American College of Veterinary Internal Medicine media release